 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk [0m
[34mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes MINOCYCLINE increase or decrease the risk [0m
[32mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"MINOCYCLINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: MINOCYCLINE: use_in_specific_populations: [0m[1;31m8[0m[31m USE IN SPECIFIC POPULATIONS â€¢ Minocycline like other tetracycline-class drugs can cause fetal harm when administered to a pregnant woman. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m
[1;31m8.1[0m[31m [0m[1;31m)[0m[31m â€¢ The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of teeth. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m[1;31m8.4[0m[31m [0m[1;31m)[0m[31m [0m[1;31m8.1[0m[31m Pregnancy Teratogenic Effects: Pregnancy Category D [0m[1;31m[[0m[31m see [0m
[31mWARNINGS AND PRECAUTIONS [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Minocycline hydrochloride extended-release tablets should not be used during pregnancy. If the patient becomes pregnant while taking this drug, the patient should be [0m
[31mapprised of the potential hazard to the fetus and stop treatment immediately. There are no adequate and well-controlled studies on the use of minocycline in pregnant women. MINOCYCLINE: [0m
[31muse_in_specific_populations: Minocycline, like other tetracycline-class drugs, crosses the placenta and may cause fetal harm when administered to a pregnant woman. Rare spontaneous reports of [0m
[31mcongenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. Only limited information is available regarding these reports; [0m
[31mtherefore, no conclusion on causal association can be established. Minocycline induced skeletal malformations [0m[1;31m([0m[31mbent limb bones[0m[1;31m)[0m[31m in fetuses when administered to pregnant rats and rabbits in doses of [0m[1;31m30[0m
[31mmg/kg/day and [0m[1;31m100[0m[31m mg/kg/day, respectively, [0m[1;31m([0m[31mresulting in approximately [0m[1;31m3[0m[31m times and [0m[1;31m2[0m[31m times, respectively, the systemic exposure to minocycline observed in patients as a result of use of minocycline [0m
[31mhydrochloride extended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: use_in_specific_populations: Reduced mean fetal body weight was observed in studies in which minocycline was administered to pregnant rats at a [0m
[31mdose of [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mwhich resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. [0m
[31mMinocycline was assessed for effects on peri-and post-natal development of rats in a study that involved oral administration to pregnant rats from day [0m[1;31m6[0m[31m of gestation through the period of lactation [0m
[1;31m([0m[31mpostpartum day [0m[1;31m20[0m[1;31m)[0m[31m, at dosages of [0m[1;31m5[0m[31m, [0m[1;31m10[0m[31m, or [0m[1;31m50[0m[31m mg/kg/day. In this study, body weight gain was significantly reduced in pregnant females that received [0m[1;31m50[0m[31m mg/kg/day [0m[1;31m([0m[31mresulting in approximately [0m[1;31m2.5[0m[31m [0m
[31mtimes the systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: use_in_specific_populations: No effects of [0m
[31mtreatment on the duration of the gestation period or the number of live pups born per litter were observed. Gross external anomalies observed in F1 pups [0m[1;31m([0m[31moffspring of animals that received [0m
[31mminocycline[0m[1;31m)[0m[31m included reduced body size, improperly rotated forelimbs, and reduced size of extremities. No effects were observed on the physical development, behavior, learning ability, or [0m
[31mreproduction of F1 pups, and there was no effect on gross appearance of F2 pups [0m[1;31m([0m[31moffspring of F1 animals[0m[1;31m)[0m[31m. [0m[1;31m8.3[0m[31m Nursing Mothers Tetracycline-class antibiotics are excreted in human milk. Because of the[0m
[31mpotential for serious adverse effects on bone and tooth development in nursing infants from the tetracycline-class antibiotics, a decision should be made whether to discontinue nursing or discontinue [0m
[31mthe drug, taking into account the importance of the drug to the mother [0m[31m. [0m[1;31m8[0m[31m. MINOCYCLINE: use_in_specific_populations: [0m[1;31m4[0m[31m Pediatric Use Minocycline hydrochloride extended-release tablet is indicated to [0m
[31mtreat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients [0m[1;31m12[0m[31m years and older. Safety and effectiveness in pediatric patients below the age of [0m[1;31m12[0m[31m has not been [0m
[31mestablished. Use of tetracycline-class antibiotics below the age of [0m[1;31m8[0m[31m is not recommended due to the potential for tooth discoloration [0m[31m. [0m[1;31m8.5[0m[31m Geriatric Use Clinical studies of minocycline hydrochloride [0m
[31mextended-release tablets did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not[0m
[31midentified differences in responses between the elderly and younger patients. MINOCYCLINE: use_in_specific_populations: In general, dose selection for an elderly patient should be cautious, usually [0m
[31mstarting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy Teratogenic Effects: Pregnancy Category D [0m[1;31m[[0m[31m see WARNINGS AND PRECAUTIONS [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Minocycline hydrochloride extended-release tablets should not be used [0m
[31mduring pregnancy. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and stop treatment immediately. There are no adequate and [0m
[31mwell-controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline-class drugs, crosses the placenta and may cause fetal harm when administered to a pregnant [0m
[31mwoman. Rare spontaneous reports of congenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. Only limited information is [0m
[31mavailable regarding these reports; therefore, no conclusion on causal association can be established. MINOCYCLINE: pregnancy: Minocycline induced skeletal malformations [0m[1;31m([0m[31mbent limb bones[0m[1;31m)[0m[31m in fetuses [0m
[31mwhen administered to pregnant rats and rabbits in doses of [0m[1;31m30[0m[31m mg/kg/day and [0m[1;31m100[0m[31m mg/kg/day, respectively, [0m[1;31m([0m[31mresulting in approximately [0m[1;31m3[0m[31m times and [0m[1;31m2[0m[31m times, respectively, the systemic exposure to [0m
[31mminocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. Reduced mean fetal body weight was observed in studies in which minocycline was administered[0m
[31mto pregnant rats at a dose of [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mwhich resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use minocycline hydrochloride [0m
[31mextended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: pregnancy: Minocycline was assessed for effects on peri-and post-natal development of rats in a study that involved oral administration to pregnant rats from [0m
[31mday [0m[1;31m6[0m[31m of gestation through the period of lactation [0m[1;31m([0m[31mpostpartum day [0m[1;31m20[0m[1;31m)[0m[31m, at dosages of [0m[1;31m5[0m[31m, [0m[1;31m10[0m[31m, or [0m[1;31m50[0m[31m mg/kg/day. In this study, body weight gain was significantly reduced in pregnant females that [0m
[31mreceived [0m[1;31m50[0m[31m mg/kg/day [0m[1;31m([0m[31mresulting in approximately [0m[1;31m2.5[0m[31m times the systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. No [0m
[31meffects of treatment on the duration of the gestation period or the number of live pups born per litter were observed. Gross external anomalies observed in F1 pups [0m[1;31m([0m[31moffspring of animals that received [0m
[31mminocycline[0m[1;31m)[0m[31m included reduced body size, improperly rotated forelimbs, and reduced size of extremities. MINOCYCLINE: pregnancy: No effects were observed on the physical development, behavior, learning[0m
[31mability, or reproduction of F1 pups, and there was no effect on gross appearance of F2 pups [0m[1;31m([0m[31moffspring of F1 animals[0m[1;31m)[0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: spl_id         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: product_ndc         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: spl_set_id         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: package_ndc         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: clinical_studies_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"14[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"14[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"15[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"15[0m[31m%"[0m[31m/[0m[31m> <tbody> <tr> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Subject&#x2019;s Weight [0m[1;31m([0m[31mlbs[0m[1;31m)[0m[31m <[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Subject&#x2019;s Weight [0m[1;31m([0m[31mkg[0m[1;31m)[0m[31m <[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Available Caplet Strength [0m[1;31m([0m[31mmg[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Actual MINOCYCLINE: clinical_studies_table: mg/kg<[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> [0m
[31m<paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Dose <[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m99[0m[31m &#x2013; [0m[1;31m131[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m45[0m[31m &#x2013; [0m[1;31m59[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m45[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1[0m[31m &#x2013; [0m[1;31m0[0m[31m. MINOCYCLINE: clinical_studies_table: [0m[1;31m76[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule [0m
[31m"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m132[0m[31m &#x2013; [0m[1;31m199[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m60[0m[31m &#x2013; [0m[1;31m90[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m90[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1[0m[31m. MINOCYCLINE: clinical_studies_table: [0m[1;31m5[0m[31m &#x2013;[0m
[1;31m1[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m200[0m[31m &#x2013; [0m[1;31m300[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31m<paragraph>[0m[1;31m91[0m[31m &#x2013; [0m[1;31m136[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m135[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1.48[0m[31m &#x2013; [0m[1;31m0[0m[31m. MINOCYCLINE: clinical_studies_table: [0m[1;31m99[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <[0m[31m/[0m[31mtbody[0m[31m> <[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:MINOCYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"MINOCYCLINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does MINOCYCLINE increase or decrease the risk of [0m
[31mmortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes MINOCYCLINE increase or decrease the risk [0m
[32mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"MINOCYCLINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: MINOCYCLINE: use_in_specific_populations: [0m[1;31m8[0m[31m USE IN SPECIFIC POPULATIONS â€¢ Minocycline like other tetracycline-class drugs can cause fetal harm when administered to a pregnant woman. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m
[1;31m8.1[0m[31m [0m[1;31m)[0m[31m â€¢ The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of teeth. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m , [0m[1;31m8.4[0m[31m [0m[1;31m)[0m[31m [0m[1;31m8.1[0m[31m Pregnancy Teratogenic Effects: Pregnancy Category D [0m[1;31m[[0m[31m see [0m
[31mWARNINGS AND PRECAUTIONS [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Minocycline hydrochloride extended-release tablets should not be used during pregnancy. If the patient becomes pregnant while taking this drug, the patient should be [0m
[31mapprised of the potential hazard to the fetus and stop treatment immediately. There are no adequate and well-controlled studies on the use of minocycline in pregnant women. MINOCYCLINE: [0m
[31muse_in_specific_populations: Minocycline, like other tetracycline-class drugs, crosses the placenta and may cause fetal harm when administered to a pregnant woman. Rare spontaneous reports of [0m
[31mcongenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. Only limited information is available regarding these reports; [0m
[31mtherefore, no conclusion on causal association can be established. Minocycline induced skeletal malformations [0m[1;31m([0m[31mbent limb bones[0m[1;31m)[0m[31m in fetuses when administered to pregnant rats and rabbits in doses of [0m[1;31m30[0m
[31mmg/kg/day and [0m[1;31m100[0m[31m mg/kg/day, respectively, [0m[1;31m([0m[31mresulting in approximately [0m[1;31m3[0m[31m times and [0m[1;31m2[0m[31m times, respectively, the systemic exposure to minocycline observed in patients as a result of use of minocycline [0m
[31mhydrochloride extended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: use_in_specific_populations: Reduced mean fetal body weight was observed in studies in which minocycline was administered to pregnant rats at a [0m
[31mdose of [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mwhich resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. [0m
[31mMinocycline was assessed for effects on peri-and post-natal development of rats in a study that involved oral administration to pregnant rats from day [0m[1;31m6[0m[31m of gestation through the period of lactation [0m
[1;31m([0m[31mpostpartum day [0m[1;31m20[0m[1;31m)[0m[31m, at dosages of [0m[1;31m5[0m[31m, [0m[1;31m10[0m[31m, or [0m[1;31m50[0m[31m mg/kg/day. In this study, body weight gain was significantly reduced in pregnant females that received [0m[1;31m50[0m[31m mg/kg/day [0m[1;31m([0m[31mresulting in approximately [0m[1;31m2.5[0m[31m [0m
[31mtimes the systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: use_in_specific_populations: No effects of [0m
[31mtreatment on the duration of the gestation period or the number of live pups born per litter were observed. Gross external anomalies observed in F1 pups [0m[1;31m([0m[31moffspring of animals that received [0m
[31mminocycline[0m[1;31m)[0m[31m included reduced body size, improperly rotated forelimbs, and reduced size of extremities. No effects were observed on the physical development, behavior, learning ability, or [0m
[31mreproduction of F1 pups, and there was no effect on gross appearance of F2 pups [0m[1;31m([0m[31moffspring of F1 animals[0m[1;31m)[0m[31m. [0m[1;31m8.3[0m[31m Nursing Mothers Tetracycline-class antibiotics are excreted in human milk. Because of the[0m
[31mpotential for serious adverse effects on bone and tooth development in nursing infants from the tetracycline-class antibiotics, a decision should be made whether to discontinue nursing or discontinue [0m
[31mthe drug, taking into account the importance of the drug to the mother [0m[31m. [0m[1;31m8[0m[31m. MINOCYCLINE: use_in_specific_populations: [0m[1;31m4[0m[31m Pediatric Use Minocycline hydrochloride extended-release tablet is indicated to [0m
[31mtreat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients [0m[1;31m12[0m[31m years and older. Safety and effectiveness in pediatric patients below the age of [0m[1;31m12[0m[31m has not been [0m
[31mestablished. Use of tetracycline-class antibiotics below the age of [0m[1;31m8[0m[31m is not recommended due to the potential for tooth discoloration [0m[31m. [0m[1;31m8.5[0m[31m Geriatric Use Clinical studies of minocycline hydrochloride [0m
[31mextended-release tablets did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not[0m
[31midentified differences in responses between the elderly and younger patients. MINOCYCLINE: use_in_specific_populations: In general, dose selection for an elderly patient should be cautious, usually [0m
[31mstarting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy Teratogenic Effects: Pregnancy Category D [0m[1;31m[[0m[31m see WARNINGS AND PRECAUTIONS [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[1;31m][0m[31m Minocycline hydrochloride extended-release tablets should not be used [0m
[31mduring pregnancy. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and stop treatment immediately. There are no adequate and [0m
[31mwell-controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline-class drugs, crosses the placenta and may cause fetal harm when administered to a pregnant [0m
[31mwoman. Rare spontaneous reports of congenital anomalies including limb reduction have been reported with minocycline use in pregnancy in post-marketing experience. Only limited information is [0m
[31mavailable regarding these reports; therefore, no conclusion on causal association can be established. MINOCYCLINE: pregnancy: Minocycline induced skeletal malformations [0m[1;31m([0m[31mbent limb bones[0m[1;31m)[0m[31m in fetuses [0m
[31mwhen administered to pregnant rats and rabbits in doses of [0m[1;31m30[0m[31m mg/kg/day and [0m[1;31m100[0m[31m mg/kg/day, respectively, [0m[1;31m([0m[31mresulting in approximately [0m[1;31m3[0m[31m times and [0m[1;31m2[0m[31m times, respectively, the systemic exposure to [0m
[31mminocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. Reduced mean fetal body weight was observed in studies in which minocycline was administered[0m
[31mto pregnant rats at a dose of [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mwhich resulted in approximately the same level of systemic exposure to minocycline as that observed in patients who use minocycline hydrochloride [0m
[31mextended-release tablets[0m[1;31m)[0m[31m. MINOCYCLINE: pregnancy: Minocycline was assessed for effects on peri-and post-natal development of rats in a study that involved oral administration to pregnant rats from [0m
[31mday [0m[1;31m6[0m[31m of gestation through the period of lactation [0m[1;31m([0m[31mpostpartum day [0m[1;31m20[0m[1;31m)[0m[31m, at dosages of [0m[1;31m5[0m[31m, [0m[1;31m10[0m[31m, or [0m[1;31m50[0m[31m mg/kg/day. In this study, body weight gain was significantly reduced in pregnant females that [0m
[31mreceived [0m[1;31m50[0m[31m mg/kg/day [0m[1;31m([0m[31mresulting in approximately [0m[1;31m2.5[0m[31m times the systemic exposure to minocycline observed in patients as a result of use of minocycline hydrochloride extended-release tablets[0m[1;31m)[0m[31m. No [0m
[31meffects of treatment on the duration of the gestation period or the number of live pups born per litter were observed. Gross external anomalies observed in F1 pups [0m[1;31m([0m[31moffspring of animals that received [0m
[31mminocycline[0m[1;31m)[0m[31m included reduced body size, improperly rotated forelimbs, and reduced size of extremities. MINOCYCLINE: pregnancy: No effects were observed on the physical development, behavior, learning[0m
[31mability, or reproduction of F1 pups, and there was no effect on gross appearance of F2 pups [0m[1;31m([0m[31moffspring of F1 animals[0m[1;31m)[0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: spl_id         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: product_ndc         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: spl_set_id         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: package_ndc         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: clinical_studies_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"14[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"14[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"15[0m[31m%"[0m[31m/[0m[31m> <col [0m[31mwidth[0m[31m=[0m[31m"15[0m[31m%"[0m[31m/[0m[31m> <tbody> <tr> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Subject&#x2019;s Weight [0m[1;31m([0m[31mlbs[0m[1;31m)[0m[31m <[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Subject&#x2019;s Weight [0m[1;31m([0m[31mkg[0m[1;31m)[0m[31m <[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Available Caplet Strength [0m[1;31m([0m[31mmg[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Actual MINOCYCLINE: clinical_studies_table: mg/kg<[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> [0m
[31m<paragraph> <content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Dose <[0m[31m/[0m[31mcontent[0m[31m> <[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m99[0m[31m &#x2013; [0m[1;31m131[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m45[0m[31m &#x2013; [0m[1;31m59[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m45[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1[0m[31m &#x2013; [0m[1;31m0[0m[31m. MINOCYCLINE: clinical_studies_table: [0m[1;31m76[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule [0m
[31m"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m132[0m[31m &#x2013; [0m[1;31m199[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m60[0m[31m &#x2013; [0m[1;31m90[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m90[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1[0m[31m. MINOCYCLINE: clinical_studies_table: [0m[1;31m5[0m[31m &#x2013;[0m
[1;31m1[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m200[0m[31m &#x2013; [0m[1;31m300[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31m<paragraph>[0m[1;31m91[0m[31m &#x2013; [0m[1;31m136[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m135[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1.48[0m[31m &#x2013; [0m[1;31m0[0m[31m. MINOCYCLINE: clinical_studies_table: [0m[1;31m99[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <[0m[31m/[0m[31mtbody[0m[31m> <[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:MINOCYCLINE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes MINOCYCLINE increase or decrease the risk [0m
[32mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"MINOCYCLINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does MINOCYCLINE increase or decrease the risk of [0m
[31mmortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"MINOCYCLINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mMINOCYCLINE[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mMINOCYCLINE[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"MINOCYCLINE"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"MINOCYCLINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: MINOCYCLINE: openfda: brand_name         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: clinical_studies_table: [0m[1;31m76[0m[1;31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m132[0m[31m &#x2013; [0m[1;31m199[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m60[0m[31m &#x2013; [0m[1;31m90[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m90[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1[0m[31m. MINOCYCLINE: clinical_studies_table: [0m[1;31m5[0m[31m &#x2013; [0m[1;31m1[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <tr> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m200[0m[31m &#x2013; [0m[1;31m300[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m91[0m[31m &#x2013; [0m[1;31m136[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m135[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> <paragraph>[0m[1;31m1.48[0m[31m &#x2013; [0m[1;31m0[0m[31m. MINOCYCLINE: [0m
[31mclinical_studies_table: [0m[1;31m99[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m> <[0m[31m/[0m[31mtd[0m[31m> <[0m[31m/[0m[31mtr[0m[31m> <[0m[31m/[0m[31mtbody[0m[31m> <[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: manufacturer_name         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: spl_product_data_elements: Minocycline Hydrochloride Minocycline Hydrochloride MINOCYCLINE HYDROCHLORIDE MINOCYCLINE FERROSOFERRIC OXIDE SILICON DIOXIDE LACTOSE MONOHYDRATE [0m
[31mMAGNESIUM STEARATE TITANIUM DIOXIDE TRIACETIN FERRIC OXIDE YELLOW HYPROMELLOSE [0m[1;31m2208[0m[31m [0m[1;31m([0m[1;31m15000[0m[31m MPA.S[0m[1;31m)[0m[31m HYPROMELLOSE [0m[1;31m2910[0m[31m [0m[1;31m([0m[1;31m15[0m[31m MPA.S[0m[1;31m)[0m[31m capsule shaped I113 Minocycline Hydrochloride Minocycline Hydrochloride [0m
[31mMINOCYCLINE HYDROCHLORIDE MINOCYCLINE SILICON DIOXIDE LACTOSE MONOHYDRATE MAGNESIUM STEARATE TITANIUM DIOXIDE TRIACETIN FERRIC OXIDE YELLOW FD&C YELLOW NO. MINOCYCLINE: spl_product_data_elements: [0m[1;31m6[0m[31m [0m
[31mFERRIC OXIDE RED HYPROMELLOSE [0m[1;31m2208[0m[31m [0m[1;31m([0m[1;31m15000[0m[31m MPA.S[0m[1;31m)[0m[31m HYPROMELLOSE [0m[1;31m2910[0m[31m [0m[1;31m([0m[1;31m15[0m[31m MPA.S[0m[1;31m)[0m[31m light capsule shaped I112 Minocycline Hydrochloride Minocycline Hydrochloride MINOCYCLINE HYDROCHLORIDE MINOCYCLINE [0m
[31mSILICON DIOXIDE LACTOSE MONOHYDRATE MAGNESIUM STEARATE TITANIUM DIOXIDE TRIACETIN FERRIC OXIDE YELLOW HYPROMELLOSE [0m[1;31m2208[0m[31m [0m[1;31m([0m[1;31m15000[0m[31m MPA.S[0m[1;31m)[0m[31m HYPROMELLOSE [0m[1;31m2910[0m[31m [0m[1;31m([0m[1;31m15[0m[31m MPA. MINOCYCLINE: spl_product_data_elements:[0m
[1;31m)[0m[31m light capsule shaped I111         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: contraindications: [0m[1;31m4[0m[31m CONTRAINDICATIONS This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. This drug is contraindicated in [0m
[31mpersons who have shown hypersensitivity to any of the tetracyclines.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: openfda: generic_name         [0m
[31mSOURCE:MINOCYCLINE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Minocycline is a tetracycline antibiotic that is used to treat a variety of infections. It is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. It is also[0m
[32mnot recommended for use during pregnancy due to the potential for fetal harm, and it should be used with caution in nursing mothers and the elderly. The drug comes in various forms and strengths, and [0m
[32mits use includes treatment for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients [0m[1;32m12[0m[32m years and older.[0m

[32mSOURCE: MINOCYCLINE label[0m
[32mEXTRACT_START_END: MINOCYCLINE: contraindications: [0m[1;32m4[0m[32m CONTRAINDICATIONS [0m[32m...[0m[32m to any of the tetracyclines.[0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Minocycline is a tetracycline antibiotic[0m
[34mthat is used to treat a variety of infections. It is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. It is also not recommended for use during pregnancy due to [0m
[34mthe potential for fetal harm, and it should be used with caution in nursing mothers and the elderly. The drug comes in various forms and strengths, and its use includes treatment for inflammatory [0m
[34mlesions of non-nodular moderate to severe acne vulgaris in patients [0m[1;34m12[0m[34m years and older.[0m

[34mSOURCE: MINOCYCLINE label[0m
[34mEXTRACT_START_END: MINOCYCLINE: contraindications: [0m[1;34m4[0m[34m CONTRAINDICATIONS [0m[34m...[0m[34m to any of the tetracyclines.[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I requested information from FDAHandler regarding the impact of MINOCYCLINE on mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler provided information about MINOCYCLINE, stating its uses and contraindications, but did not provide specific information regarding its impact on mortality after myocardial [0m
[32minfarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I requested information from FDAHandler regarding the impact of MINOCYCLINE on mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler provided information about MINOCYCLINE, stating its uses and contraindications, but did not provide specific information regarding its impact on mortality after myocardial [0m
[34minfarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does MINOCYCLINE increase or decrease the risk of mortality after myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I requested information from FDAHandler regarding the impact of MINOCYCLINE on mortality after myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler provided information about MINOCYCLINE, stating its uses and contraindications, but did not provide specific information regarding its impact on mortality after myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDAHandler provided information about the uses and contraindications of MINOCYCLINE, which is a tetracycline antibiotic used to treat various infections. However, the FDAHandler did not provide [0m
[32mspecific information regarding the impact of MINOCYCLINE on mortality after myocardial infarction. Therefore, based on the available FDA label data, I cannot determine whether MINOCYCLINE increases or[0m
[32mdecreases the risk of mortality after myocardial infarction.[0m
